Neuromodulation News and Research

RSS

Neurostimulation effective for management of chronic pain

St. Jude Medical, Inc., a global medical device company, today announced two-year results in a post-market clinical study evaluating neurostimulation (spinal cord stimulation) for the management of chronic low back pain. Presented at the 14th annual North American Neuromodulation Society (NANS) meeting in Las Vegas, the study found that 70 percent of neurostimulation patients reported overall pain relief of 50 percent or better at their final two-year visit.

4 Dec 2010

Spinal Modulation's Dorsal Root Ganglion Stimulation Pilot Clinical Trial results to be presented at 14th NANS

SPINAL MODULATION, Inc., a privately held medical device company focused on developing devices to treat chronic pain, today announced that the results of its prospective, multicenter Dorsal Root Ganglion (DRG) Stimulation Clinical Trial will be presented by David Caraway, MD, PhD, Timothy Deer, MD and Robert Levy, MD, PhD at the 14th Annual North American Neuromodulation Society (NANS) meeting.

30 Nov 2010

Palmetto GBA to cover PTNS therapy for patients with overactive bladder

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced that Palmetto GBA for California, Nevada and Hawaii, a regional Medicare carrier, now covers posterior tibial nerve stimulation using the Urgent PC Neuromodulation System for the treatment of the symptoms of overactive bladder.

20 Nov 2010

FDA clears Multi-Lead Trialing Cable for SCS therapy

Medtronic Inc., the leader in spinal cord stimulation for more than 25 years, today announced U.S. Food and Drug Administration (FDA) clearance and the global launch of the Multi-Lead Trialing Cable for use in the patient screening test for Medtronic spinal cord stimulation (SCS) therapy.

19 Nov 2010

Boston Scientific announces first implantation of Vercise Deep Brain Stimulation System in Parkinson's disease trial

Boston Scientific Corporation today announced the first implantation of its Vercise™ Deep Brain Stimulation (DBS) System as part of the VANTAGE clinical trial. VANTAGE is a multi-center, prospective trial designed to examine the improvement of motor function in approximately 40 European patients implanted with the Vercise DBS System for the treatment of Parkinson's disease.

10 Nov 2010

NICE issues PTNS guidance for overactive bladder

Uroplasty, Inc. announced today that the United Kingdom's National Institute for Health and Clinical Excellence (NICE) issued a guidance document titled "Percutaneous Posterior Tibial Nerve Stimulation for Overactive Bladder Syndrome," reinforcing the safety and effectiveness of PTNS for overactive bladder.

28 Oct 2010

NMT releases new device for treatment of post-operative nausea

Neurowave Medical Technologies™ today announced the release of an innovative new device for the treatment of post-operative nausea, medically referred to as emesis. Reletex™ is a novel transdermal neuromodulation device that is non-invasive and drug-free, and has been demonstrated to alleviate nausea when used as an adjunct to anti-emetics.

20 Oct 2010

St. Jude Medical third quarter net sales increase 7% to $1.240 billion

St. Jude Medical, Inc. today reported sales and net earnings for the third quarter ended October 2, 2010.

20 Oct 2010

Early diagnosis of interstitial cystitis can improve quality of life

October is interstitial cystitis (IC) awareness month and this year's campaign is dedicated to fighting discrimination.

5 Oct 2010

St. Jude Medical receives Japanese approval for Eon Mini spinal cord stimulation system

St. Jude Medical, Inc., a global medical device company, today announced regulatory approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) of the Eon Mini™ spinal cord stimulation (SCS) system. The world's smallest, longest-lasting rechargeable neurostimulator, the Eon Mini device is the first rechargeable spinal cord stimulator to be approved for use in Japan.

30 Sep 2010

SCS, PNS prove to be effective tools in treating chronic pain: NANS, ASIPP

Afflicting countless people worldwide, chronic pain is a largely misunderstood and under-treated disease that forever alters the lives of more than 50 million Americans each year.

28 Sep 2010

Study: PTNS offers an effective treatment option for detrusor overactivity incontinence

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today highlighted results of a study "Percutaneous Tibial Nerve Stimulation Effects on Detrusor Overactivity Incontinence Are Not Due to a Placebo Effect A Randomized, Double-Blind, Placebo Controlled Trial," to be published in the November 2010 print edition of THE JOURNAL OF UROLOGY.

24 Sep 2010

St. Jude Medical granted European CE Mark for Athena deep brain stimulation therapy management system

St. Jude Medical, Inc., a global medical device company, today announced European CE Mark approval of its new Athena™ programmer, a deep brain stimulation (DBS) therapy management system. This next-generation platform offers clinicians a powerful yet easy-to-use interface that enables them to set or adjust therapeutic parameters to optimize patient results.

20 Sep 2010

$ONS trial results show promise for treating medically refractory chronic migraines: ONSTIM study$

ONS trial results show promise for treating medically refractory chronic migraines: ONSTIM study

Medtronic, Inc. announced that data from a multicenter, prospective, randomized, blinded, feasibility trial published today show promise for occipital nerve stimulation for treating medically refractory chronic migraines and support the need for further controlled study of the treatment. The study, called Occipital Nerve Stimulation for the Treatment of Intractable Migraine, included severely debilitated patients who had regularly experienced 15 or more headache days per month that were not responsive to currently available medical therapies.

18 Sep 2010

Medtronic Deep Brain Stimulation Therapy for severe epilepsy receives CE Mark approval

Medtronic, Inc. today announced that the company has received CE (Conformité Européenne) Mark approval for Medtronic Deep Brain Stimulation (DBS) Therapy in Europe as adjunctive treatment for partial-onset seizures in adults with medically refractory epilepsy. DBS therapy for epilepsy delivers controlled electrical pulses to a target in the brain called the anterior nucleus of the thalamus, which is part of a circuit involved in seizures.

17 Sep 2010

Medtronic 2011 first quarter revenue decreases 4%

Medtronic, Inc. today announced financial results for its first quarter of fiscal year 2011, which ended July 30, 2010.

24 Aug 2010

FDA approves two SCS leads for use with Boston Scientific's Precision Plus Spinal Cord Stimulator System

Boston Scientific Corporation today announced U.S. Food and Drug Administration approval of two spinal cord stimulation (SCS) leads for use with its Precision Plus™ Spinal Cord Stimulator System, the world's first rechargeable SCS device for the management of chronic pain of the trunk and/or limbs. The Linear™ 3-4 and Linear™ 3-6 Percutaneous Leads offer wider contact spacing to expand the lead choices available to physicians. The Company plans to launch the products immediately in the U.S.; they were launched in Europe and other international markets earlier.

30 Jul 2010

Medtronic launches Defeat-HF clinical trial to evaluate SCS for heart failure

Medtronic, Inc. today announced the global launch of the Defeat-HF (Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure) clinical trial. It is the industry's first prospective, randomized study evaluating the clinical feasibility of spinal cord stimulation, or neurostimulation, to improve clinical signs and symptoms of heart failure.

30 Jul 2010

St. Jude Medical second-quarter net sales increase 11% to $1.313 billion

St. Jude Medical, Inc., a global medical device company, today reported sales and net earnings for the second quarter ended July 3, 2010.

23 Jul 2010

Uroplasty broadens neuromodulation patent portfolio

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, announced today the issuance of United States Patent No. 7,729,772 which covers a method for using an implantable neuromodulation system in the treatment of urinary incontinence by neuromodulation or stimulation of the tibial nerve. The neuromodulation system includes a portable, external transmitter and a receiver implanted subcutaneously in the leg or ankle near the tibial nerve.

1 Jul 2010

Neuromodulation News and Research

Neurostimulation effective for management of chronic pain

Spinal Modulation's Dorsal Root Ganglion Stimulation Pilot Clinical Trial results to be presented at 14th NANS

Palmetto GBA to cover PTNS therapy for patients with overactive bladder

FDA clears Multi-Lead Trialing Cable for SCS therapy

Boston Scientific announces first implantation of Vercise Deep Brain Stimulation System in Parkinson's disease trial

NICE issues PTNS guidance for overactive bladder

NMT releases new device for treatment of post-operative nausea

St. Jude Medical third quarter net sales increase 7% to $1.240 billion

Early diagnosis of interstitial cystitis can improve quality of life

St. Jude Medical receives Japanese approval for Eon Mini spinal cord stimulation system

SCS, PNS prove to be effective tools in treating chronic pain: NANS, ASIPP

Study: PTNS offers an effective treatment option for detrusor overactivity incontinence

St. Jude Medical granted European CE Mark for Athena deep brain stimulation therapy management system

ONS trial results show promise for treating medically refractory chronic migraines: ONSTIM study

Medtronic Deep Brain Stimulation Therapy for severe epilepsy receives CE Mark approval

Medtronic 2011 first quarter revenue decreases 4%

FDA approves two SCS leads for use with Boston Scientific's Precision Plus Spinal Cord Stimulator System

Medtronic launches Defeat-HF clinical trial to evaluate SCS for heart failure

St. Jude Medical second-quarter net sales increase 11% to $1.313 billion

Uroplasty broadens neuromodulation patent portfolio

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News